Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:NVAX 6 November 2025 - 31 January 2026

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares fell 6.4% to $8.85 at Friday’s close, underperforming the broader market. Trading volume topped 5 million shares, above the 50-day average. Investors are watching for updates on partner-driven cash, including a $30 million upfront payment expected in Q1 2026 from a license deal. Novavax delayed its profitability target to 2028 and projects 2026 adjusted revenue of $185–$205 million.
31 January 2026
····
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer shares closed up 0.8% at $26.10 Thursday, trading between $25.75 and $26.31. The gain followed news of a non-exclusive deal with Novavax for access to its Matrix‑M adjuvant, worth $30 million upfront. U.S. officials have reversed universal vaccine recommendations, shifting to “shared clinical-decision-making.” Pfizer CEO Albert Bourla blamed policy rhetoric for falling vaccination rates.
23 January 2026
···
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares rose 0.8% to $25.73 Wednesday after the company agreed to exit its ViiV Healthcare stake, with Shionogi paying $1.875 billion and raising its holding to 21.7%. Pfizer also secured rights to Novavax’s Matrix-M adjuvant for $30 million upfront. Both deals await regulatory clearance and do not guarantee near-term earnings growth. Investors await Pfizer’s Q4 results on Feb. 3.
21 January 2026
····
NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Novavax (NASDAQ: NVAX) closed at $6.91 on December 5, 2025, with a market cap near $1.1 billion. Shares are down about 20% over the past year and 94% over five years. Q2 2025 saw a surprise profit on $239 million revenue, boosted by a $175 million Sanofi milestone payment, but Q3 revenue dropped to $70 million with a net loss of $202 million. The stock trades 40% below its January high.
7 December 2025
Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax (NASDAQ: NVAX) closed at $6.47 on Friday, up 4.0% but still 44% below its 52-week high. Q3 revenue beat estimates at $70 million, though losses widened and profitability is now targeted for 2028. Shah Capital is pressuring for a sale and threatening a proxy fight. The company expanded its Sanofi partnership, securing $225 million in milestones this year.
24 November 2025
·
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax raised its FY2025 adjusted revenue outlook to $1.04–$1.06 billion after reporting Q3 revenue of $70 million, above estimates. The company posted a GAAP net loss of $202 million for the quarter, impacted by $126 million in non-cash charges tied to Maryland site consolidation and debt. Two $25 million milestone payments from Sanofi will be recognized in Q4. Cash stood at $778 million as of September 30.
6 November 2025
·····

Stock Market Today

  • InterContinental Hotels Group to Cancel 76,481 Shares Bought in Buyback
    March 20, 2026, 5:40 AM EDT. InterContinental Hotels Group (IHG) purchased 76,481 ordinary shares on March 19, 2026, through Goldman Sachs International as part of its Annual General Meeting-authorized share buyback program. The shares were acquired on the London Stock Exchange, with prices ranging from $127.05 to $131.35, averaging $129.73 per share. The company plans to cancel these shares, reducing the total shares outstanding to 150,524,341, excluding 5,431,782 shares held in treasury. This move follows instructions issued on February 17, 2026, reinforcing IHG's commitment to returning value to shareholders through share consolidation.
Go toTop